Clinical trials using vasodilators in pulmonary arterial hypertension: Where do we go from here?

Reviews on Recent Clinical Trials

Volumn 6, Issue 3, 2011, Pages 228-234

  Macchia, Alejandro ^a,b,c,d   Mariani, Javier ^b   Comignani, Pablo Dino ^c   Tognoni, Gianni ^d  

^a CEMIC   (Argentina)

^b Ciudad Autónoma de Buenos Aires   (Argentina)

^c HOSPITAL ALEMÁN   (Argentina)

^d Department of Vascular Medicine and Pharmacology   (Italy)

Author keywords

Metanalysis; Prognosis; Pulmonary arterial hypertension; Vasodilators

Indexed keywords

BOSENTAN; ENDOTHELIN RECEPTOR ANTAGONIST; ILOPROST; PHOSPHODIESTERASE V INHIBITOR; PLACEBO; PROSTACYCLIN; PROSTACYCLIN DERIVATIVE; TADALAFIL; VASODILATOR AGENT;

ARTICLE; CLINICAL TRIAL (TOPIC); EXERCISE TEST; FATALITY; HUMAN; META ANALYSIS (TOPIC); MORTALITY; PRIORITY JOURNAL; PULMONARY HYPERTENSION; SURVIVAL; SYSTEMATIC REVIEW (TOPIC); TREATMENT OUTCOME; VASODILATATION;

ANTIHYPERTENSIVE AGENTS; EPOPROSTENOL; EXERCISE TEST; EXERCISE TOLERANCE; HEMODYNAMICS; HUMANS; HYPERTENSION, PULMONARY; META-ANALYSIS AS TOPIC; PHOSPHODIESTERASE INHIBITORS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RECEPTORS, ENDOTHELIN; REVIEW LITERATURE AS TOPIC; VASODILATOR AGENTS;

EID: 80051729086     PISSN: 15748871     EISSN: 18761038     Source Type: Journal    
DOI: 10.2174/157488711796575504     Document Type: Article

References (50)

1. Gaine SP, Rubin LJ. Primary pulmonary hypertension. Lancet 1998; 352: 719-25.
2. Runo JR, Loyd JE. Primary pulmonary hypertension. Lancet 2003; 361: 1533-44.
3. Rich S, Dantzker DR, Ayres SM, et al. Primary pulmonary hypertension. A national prospective study. Ann Intern Med 1987; 107: 216-23.
4. Sandoval J, Bauerle O, Palomar A, et al. Survival in primary pulmonary hypertension. Validation of a prognostic equation. Circulation 1994; 89: 1733-44.
5. Okada O, Tanabe N, Yasuda J, et al. Prediction of life expectancy in patients with primary pulmonary hypertension. A retrospective nationwide survey from 1980-1990. Intern Med 1999; 38: 12-6.
6. Rajasekhar D, Balakrishnan KG, Venkitachalam CG, et al. Primary pulmonary hypertension: natural history and prognostic factors. Indian Heart J 1994; 46: 165-70
7. Rich S. The current treatment of pulmonary arterial hypertension: time to redefine success. Chest 2006; 130: 1198-202
8. Farber HW. The status of pulmonary arterial hypertension in 2008. Circulation 2008; 117: 2966-2968.
9. Rich S. The value of approved therapies for pulmonary arterial hypertension. Am Heart J 2007; 153: 889-890.
10. Macchia A, Marchioli R, Marfisi RM, et al. A meta-analysis of trials of pulmonary hypertension: A clinical condition looking for drugs and research methodology. Am Heart J 2007; 153: 1037-1047.
11. Rubin LJ, Mendoza J, Hood M, et al. Treatment of primary pulmonary hypertension with continuous intravenous prostacyclin (epoprostenol). Ann Intern Med 1990; 112: 485-91.
12. Barst RJ, Rubin LJ, Long WA, et al. A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. N Engl J Med 1996; 334: 296-301.
13. Badesch DB, Tapson VF, McGoon MD, et al. Continuous intravenous epoprostenol for pulmonary hypertension due to the scleroderma spectrum of disease. Ann Intern Med 2000; 132: 425-34.
14. Olschewski H, Simonneau G, Galiè N, et al. Aerosolized Iloprost Randomized Study Group. Inhaled iloprost for severe pulmonary hypertension. N Engl J Med 2002; 347: 322-9.
15. Galiè N, Humbert M, Vachiéry JL, et al. Effects of beraprost sodium, an oral prostacyclin analogue, in patients with pulmonary arterial hypertension: a randomized, double-blind, placebo-controlled trial. J Am Coll Cardiol 2002; 39: 1496-502.
16. Simonneau G, Barst RJ, Galie N, et al. Continuous subcutaneous infusion of treprostinil, a prostacyclin analogue, in patients with pulmonary arterial hypertension: a double-blind, randomized, placebo- controlled trial. Am J Respir Crit Care Med 2002; 165: 800-4.
17. Barst RJ, McGoon M, McLaughlin V, et al. Beraprost therapy for pulmonary arterial hypertension. J Am Coll Cardiol 2003; 41: 2119-25.
18. Channick RN, Simonneau G, Sitbon O, et al. Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomised placebo-controlled study. Lancet 2001; 358: 1119-23.
19. Rubin LJ, Badesch DB, Barst RJ, et al. Bosentan therapy for pulmonary arterial hypertension. N Engl J Med 2002; 346: 896-903.
20. Barst RJ, Langleben D, Frost A, et al. Sitaxsentan therapy for pulmonary arterial hypertension. Am J Respir Crit Care Med 2004; 169: 441-7.
21. Humbert M, Barst RJ, Robbins IM, et al. Combination of bosentan with epoprostenol in pulmonary arterial hypertension: BREATHE- 2. Eur J Respir 2004; 24: 353-9.
22. Ghofrani HA, Wiedemann R, Rose F, et al. Combination therapy with oral sildenafil and inhaled iloprost for severe pulmonary hypertension. Ann Intern Med 2002; 136: 515-22.
23. Ghofrani HA, Wiedemann R, Rose F, et al. Sildenafil for treatment of lung fibrosis and pulmonary hypertension: a randomized controlled trial. Lancet 2002; 360: 895-900.
24. Sastry BK, Narasimhan C, Reddy NK, et al. Clinical efficacy of sildenafil in primary pulmonary hypertension: a randomized, placebo- controlled, double-blind, crossover study. J Am Coll Cardiol 2004; 43: 1149-53.
25. Galiè N, Ghofrani HA, Torbicki A, et al. Sildenafil Use in Pulmonary Arterial Hypertension (SUPER) Study Group. Sildenafil citrate therapy for pulmonary arterial hypertension. N Engl J Med 2005; 353: 2148-57.
26. Wilkins MR, Paul GA, Strange JW, et al. Sildenafil versus Endothelin Receptor Antagonist for Pulmonary Hypertension (SERAPH) Study. Am J Respir Crit Care Med 2005; 171: 1292-7.
27. Galie N, Olschewski H, Oudiz RJ, et al. Ambrisentan for the treatment of pulmonary arterial hypertension results of the ambrisentan in pulmonary arterial hypertension, randomized, double-blind, placebo- controlled, multicenter, efficacy (ARIES) study 1 and 2. Circulation 2008; 117: 3010-3019.
28. Barst RJ, Langleben D, Badesch D, et al. Treatment of pulmonary arterial hypertension with the selective endothelin-a receptor antagonist sitaxsentan. J Am Coll Cardiol 2006; 47: 2049-56.
29. Galie N, Beghetti M, Gatzoulis MA, et al. Randomized Trial of Endothelin Antagonist Therapy-5 (BREATHE-5) Investigators. Circulation 2006; 114; 48-54.
30. Galiè N, Rubin Lj, Hoeper M, et al. Treatment of patients with mildly symptomatic pulmonary arterial hypertension with bosentan (EARLY study): a double-blind, randomised controlled trial. Lancet 2008; 371: 2093-2100
31. Simonneau G, Rubin LJ, Galiè N, et al. Addition of sildenafil to long-term intravenous epoprostenol therapy in patients with pulmonary arterial hypertension: a randomized trial. Ann Intern Med 2008; 149: 521-530.
32. Singh TP, Rohit M, Grover A, et al. A randomized, placebocontrolled, double-blind, crossover study to evaluate the efficacy of oral sildenafil therapy in severe pulmonary artery hypertension. Am Heart J 2006; 151: 851.e1-5.
33. Galiè N, Brundage BH, Ghofrani HA, et al. Tadalafil therapy for pulmonary arterial hypertension. Circulation 2009 9; 119: 2894-903.
34. McLaughlin VV, Oudiz RJ, et al. Randomized study of adding inhaled iloprost to existing bosentan in pulmonary arterial hypertension. Am J Respir Crit Care Med 2006; 174: 1257-63
35. Hoeper MM, Leuchte H, Halank M, et al. Combining inhaled iloprost with bosentan in patients with idiopathic pulmonary arterial hypertension. Eur Respir J 2006; 28: 691-4.
36. Macchia A, Marchioli R, Tognoni G. Systematic review of trials using vasodilators in pulmonary arterial hypertension: Why a new approach is needed. Am Heart J 2010; 159: 245-57
37. Miyamoto S, Nagaya N, Satoh T y col. Clinical Correlates and Prognostic Significance of Six-minute Walk Test in Patients with Primary Pulmonary Hypertension. Am J Respir Crit Care Med 2000; 161: 487-492.
38. Paciocco G, Martinez FJ, Bossone E y col. Oxygen desaturation on the six-minute walk test and mortality in untreated primary pulmonary hypertension. Eur Respir J 2001; 17: 647-652.
39. Preliminary report: effect of encainide and flecainide on mortality in a randomized trial of arrhythmia suppression after myocardial infarction. The Cardiac Arrhythmia Suppression Trial (CAST) Investigators. N Engl J Med 1989; 321: 406-412.
40. Anand IS, Florea VG, Fisher L. Surrogate end points in heart failure. J Am Coll Cardiol 2002; 39: 1414-21.
41. Cohn JN, Goldstein SO, Greenberg BH, et al. A dose dependent increase in mortality with vesnarinone among patients with severe heart failure. N Engl J Med 1998; 339: 1810-16.
42. Packer M, Rouleau J, Swedberg K, et al. Effect of flosesequinan on survival in chronic heart failure. Circulation 1993; 88 (suppl 1): 1-103.
43. Galie N, Manes A, Negro L, et al. A meta-analysis of randomized controlled trials in pulmonary arterial hypertension. Eur Heart J 2009; 30: 394-403.
44. Flather MD, Yusuf S, Køber L, et al. Long-term ACE-inhibitor therapy in patients with heart failure or left-ventricular dysfunction: a systematic overview of data from individual patients. ACEInhibitor Myocardial Infarction Collaborative Group. Lancet 2000; 355: 1575-1581.
45. Brophy JM, Joseph L, Rouleau JL. Beta-blockers in congestive heart failure. A Bayesian meta-analysis. Ann Intern Med 2001; 134: 550-560.
46. Indications for fibrinolytic therapy in suspected acute myocardial infarction: collaborative overview of early mortality and major morbidity results from all randomised trials of more than 1000 patients. Fibrinolytic Therapy Trialists' (FTT) Collaborative Group. Lancet 1994; 343: 311-322. Erratum in: Lancet 1994; 343: 742.
47. Antithrombotic Trialists' (ATT) Collaboration, Baigent C, Blackwell L, et al. Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. Lancet 2009; 373: 1849-1860.
48. Baigent C, Keech A, Kearney PM, et al. Cholesterol Treatment Trialists' (CTT) Collaborators. Efficacy and safety of cholesterollowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 2005; 366: 1267-1278. Erratum in: Lancet. 2008; 371: 2084. Lancet 2005; 366: 1358.
49. Mereles D, Ehlken N, Kreuscher S, et al. Exercise and respiratory training improve exercise capacity and quality of life in patients with severe chronic pulmonary hypertension. Circulation 2006; 114: 1482-1489.
50. Salzman SH. The 6-min walk test. Clinical and research role, technique, coding, and reimbursement. Chest 2009; 135: 1345-52.